ATG7 and gastric cancer: Additionally, using Transwell and CCK8 assays, we evaluated the impact of ATG7 knockdown on gastric cancer cell resistance to oxaliplatin, revealing suppressed proliferation, invasion, migration, and oxaliplatin resistance after ATG7 knockdown (Figures 6F, G) (*P < 0.05, **P < 0.01, ***P < 0.001).